Foreword
Urinary tract infection (UTI), the second most common infection of humans after pneumonia, has likely plagued the population for as long as humans have walked the face of the earth. The inception of antibiotics provided adequate therapy but did not prevent infections from recurring. While symptoms of the infections were well documented, little was known about the primary infecting pathogen, Escherichia coli. In 1976, Svanborg and colleagues demonstrated that E. coli causing acute pyelonephritis adhered in greater numbers to uroepithelial cells (1). Further research by several groups revealed that the adherence factor P fimbria was responsible. This structure was found to be comprised of a multiprotein complex with the actual adhesin placed at the tip of the fimbria. With the advent of molecular techniques, other advances arrived quickly. For example, in 1981, Welch and colleagues demonstrated that a knock out of the hemolysin gene attenuated E. coli in an intraperitoneal model (2). As discoveries abounded, some 14 years later, I teamed up with infectious diseases physician John W. Warren to edit a 15-chapter book titled Urinary Tract Infections: Molecular Pathogenesis and Clinical Management. This treatise covered the clinical aspect of UTI (5 chapters) and the molecular mechanisms of bacterial pathogenesis of UTI (10 chapters). Now two decades have passed, and it was essential to update this broad topic. Editors Matthew A. Mulvey, David J. Klumpp, and Ann E. Stapleton have taken on the task of a second edition. The editors assembled an all-star lineup to cover the topic of clinical aspects of UTIs in eight chapters that include the anatomical and physiological aspects of UTI, clinical presentations, diagnosis and treatment, infections in children, involvement of the vaginal microbiome, asymptomatic UTI, prostatitis, pyelonephritis, and urosepsis (the most serious complication). In the second section (12 chapters), experts deal with reservoirs of infection, antimicrobial resistance, phylogeny, virulence, and fitness factors including exotoxins, structure of adhesins, adaptive mutations, and intracellular persistence, and this section includes chapters on other important uropathogens: Proteus mirabilis, Klebsiella pneumoniae, and Gram-positive pathogens. In the final section on host responses to UTI and emerging therapeutics (4 chapters), authors summarize the host response to UTI, innate immunity, sensation and pain in the bladder, and drug and vaccine development. Overall, this volume brings us up to date on the broad topic of UTI. Those interested in these common infections, whether it be in the laboratory or the clinic, will find the second 
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For centuries the pain and other symptoms associated with urinary tract infections (UTIs) were erroneously ascribed to the wrath of gods, bile, phlegm, bad air, or numerous other culprits. The treatments for UTIs were at times equally off-target and included the use of bleeding and enemas, while the administration of narcotics and certain herbs provided palliative support. In the late 1800s, as evidence for the germ theory of disease mounted in the wake of Pasteur and Koch, the idea that microbes were responsible for UTIs took hold. This led to the development of more efficacious treatment options, culminating in the discovery and optimization of antibiotics that continue to this day. These achievements coincided with stunning advancements in our understanding of cellular functions and developmental processes within the urinary tract, inflammatory responses, microbiology, and the roles of both innate and adaptive host defenses. Still, despite this progress, UTIs continue to rank among the most common of infectious diseases, with most UTIs being attributable to strains of uropathogenic Escherichia coli (UPEC).
In 1996, for the first edition of this book, Harry L. T. Mobley and John W. Warren assembled an all-star cast of authors to highlight the multiple host and bacterial factors that impact the pathogenesis and treatment of UTIs. A lot has happened since, including remarkable progress in our ability to sequence and manipulate both bacterial and host genomes. The first E. coli genome, belonging to the nonpathogenic strain MG1655, was sequenced in 1997, followed a few years later by the urosepsis isolate and reference UPEC strain CFT073. Today, several thousand E. coli genomes have been sequenced, including many UPEC isolates. These data have revealed a huge amount of diversity among UPEC isolates, while also shedding light on the evolution and adaptability of uropathogens. These developments overlapped with the adoption of new, more facile approaches to manipulate UPEC genomes, greatly enhancing our ability to disrupt and functionally test specific pathogen-associated loci. This work is providing leads for the generation of more efficacious therapeutics for the treatment and prevention of UTIs.
Though powerful, antibiotics have not provided a cure-all for UTIs. Many individuals endure multiple recurrent UTIs despite antibiotic treatments, while circumstances such as catheterization render others prone to chronic infections. Many UPEC isolates are now resistant to multiple antibiotics, including some drugs that should be reserved as last resort choices. In terms of medical costs and loss of life, the rapid emergence and expansion of multidrug-resistant UPEC and related strains in recent years is considered by some to be more problem- Advances in bacterial genomics have been complemented by the development of new approaches to identify UTI susceptibility factors in human populations. This work, coupled with robust UTI model systems, is beginning to explain why some individuals are more prone to UTIs, making links with innate host defense regulators, adaptive immunity, inflammatory responses, and pain perception within the urinary tract. Clinically, we are gaining a much more complete understanding of the host and bacterial factors that contribute to the onset and progression of UTIs, as well as variables that can confound treatments. These variables include patient age, sex, and catheterization, as well as the makeup of protective microbial communities within the vaginal microbiota, the gut, and potentially even the bladder itself.
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